In long-term responders to 2y first-line ICB, PET/CT-guided Tx discontinuation was associated with improved OS vs continued therapy, HR 0.35
Re-biopsy identified frequent second primary lung cancers and distinct resistance biology ➡️ local management
#lungcancer #NSCLC #immunotherapy #ICI #PETCT

This is huge.
Time of the day has an enormous impact on #immunotherapy outcome

Early immunochemo (<15:00) vs late:
📈 mPFS: 11.3 vs 5.7 mo (HR 0.40)
⏳ mOS: 28.0 vs 16.8 mo (HR 0.42)
🧬 ↑ CD8⁺ activation | similar safety

www.nature.com/articles/s41...

#lcsm #nsclc

ascopubs.org/doi/10.1200/...

#Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody–drug conjugate, for patients with #EGFR-mutated #NSCLC: Pooled analysis of phase 1 and phase 2 trials

www.annalsofoncology.org/article/S092...

Prof Xiuning Le from MDACC on EGFR PACC mutation
#LCSM #EGFR #NSCLC #uncommonEGFR

www.jtocrr.org/article/S266...

#lcsm #nsclc #zongertinib #tdxd #lungcancer

A new standard of care for mEGFR #NSCLC. #MARIPOSA (Ami + Lazer) shows significant OS (HR 0.75, 3yr 60% vs 51%, going even better over time) vs #osimertinib.
More effort is needed to manage toxicity.

#ELCC2025

Gut Microbiota in Advanced Non-small-cell Lung Cancer Receiving Chemo-immunotherapy: An Ancillary Biomarker Study from the Phase III trial JCOG2007 (NIPPON) - Journal of Thoracic Oncology www.jto.org/article/S155...

#Ivonescimab versus #pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
www.thelancet.com/journals/lan...